中国新生儿脐带血和成人外周血单个核细胞分泌三种C-C趋化因子能力的初步研究

C-C Chemokines Secretion of Lymphocyte and Monocyte in Chinese Neonate Cord Blood and Adult Peripheral Blood

目的 观察中国新生儿脐带血和成人外周血淋巴细胞和单核细胞分泌巨噬细胞炎症蛋白 1α(MIP- 1α)、MIP - 1β和受激活调节的正常T淋巴细胞表达和分泌因子 (RANTES)的能力 ,探讨影响人免疫缺陷病毒(HIV)母婴传播的可能因素。方法 Ficol密度梯度离心、贴附法分离淋巴细胞和单核细胞 ,并以免疫荧光CD3、CD14单克隆抗体鉴定。分别在PMA或LPS刺激下培养 ,ELISA法检测培养上清中三种CC趋化因子浓度。结果 17例新生儿脐带血淋巴细胞和单核细胞分泌MIP - 1α、MIP - 1β、RANTES的浓度分别为 392 0± 730、4 910± 5 90、1470± 4 10、32 4 0± 980、196 0± 130 0、2 4 0± 12 0pg/ml,2 0例成人外周血淋巴细胞和单核细胞分泌MIP - 1α、MIP - 1β、RANTES的浓度分别为 6 5 6 0± 84 0、5 810± 115 0、2 2 5 0± 5 70、30 10± 135 0、2 2 80± 870、6 90± 4 30pg/ml。脐带血淋巴细胞和单核细胞上述分泌能力低于成人血。结论 中国新生儿脐带血淋巴细胞和单核细胞分泌RANTES的能力低下 ,可能使中国新生儿比成人对HIV - 1更易感且影响发病过程。应在新生儿对HIV -

Objective To observe secretive ability of three C-C chemokines, macrophage inflammatory protein-1α(MIP-1α),MIP-1β and regulated-upon activation.normal T-cell expressed and secretory factor(RANTES)by lympocytes and moncytes of cord blood from chinese necnates and peripheral blood from chinese adults.Method Using Ficoll density-gradient centrifugation and gelatin-coated flask,the Iympocytes and monocytes were isolated from cord blood samples of seventeen Chinese neonates and peripheral blood samples of twenty Chinese adults.Purified lymphocytes and monocytes were incubated with PMA and LPS,respectively.Supernants were tested by ELISA for concentrations of MIP-1α,MIP-1β and RANTES.Results Concentrations of MIP-1α, MIP-1β and RANTES in cord blood lymphocyte and monocyte were (3920±730)pg/ml, (4910±590)pg/ml,(1470±410)pg/ml,(3240±980)pg/ml,(1960±1300)pg/ml and (240±120)pg/ml,respectively,and in adults peripheral blood were (6560±840)pg/ml,(5810±1150)pg/ml,(2250±570)pg/ml,(3010±1350) pg/ml,(2280±870)pg/ml,(690±430)pg/ml,respectively.Cord blood lymphocyte and monocyte showed diminished ability to secrete RANTES than adult peripheral blood.Conclusions The diminished RANTES secretion of cord blood lymphocyte and monocyte may be releted to the pathogenesis of Chinese neonatal HIV infection,and indicated some immunotherapies are feasible for preventing neonate from HIV mother-to-child transmission.